Literature DB >> 18977121

Dopamine antagonism inhibits anorectic behavior in an animal model for anorexia nervosa.

Linda A W Verhagen1, Mieneke C M Luijendijk, Jacquelien J G Hillebrand, Roger A H Adan.   

Abstract

Excessive physical activity is commonly described as symptom of Anorexia Nervosa (AN). Activity-based anorexia (ABA) is considered an animal model for AN. The ABA model mimics severe body weight loss and increased physical activity. Suppression of hyperactivity by olanzapine in anorectic patients as well as in ABA rats suggested a role of dopamine and/or serotonin in this trait. Here, we investigated the effect of a non-selective dopamine antagonist in the ABA model. A dose-response curve of chronic treatment with the non-selective dopaminergic antagonist cis-flupenthixol was determined in the ABA model. Treatment reduced activity levels in both ad libitum fed and food-restricted rats. Treated ABA rats reduced body weight loss and increased food intake. These data support a role for dopamine in anorexia associated hyperactivity. Interestingly, in contrast to leptin treatment, food-anticipatory activity still persists in treated ABA rats.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18977121     DOI: 10.1016/j.euroneuro.2008.09.005

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  21 in total

Review 1.  Antipsychotic agents in the treatment of anorexia nervosa: neuropsychopharmacologic rationale and evidence from controlled trials.

Authors:  Timothy D Brewerton
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

Review 2.  The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects.

Authors:  Guido K W Frank; Megan E Shott
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

3.  Dopaminergic activity and exercise behavior in anorexia nervosa.

Authors:  Sasha Gorrell; Anne G E Collins; Daniel Le Grange; Tony T Yang
Journal:  OBM Neurobiol       Date:  2020-03-23

Review 4.  Interacting Neural Processes of Feeding, Hyperactivity, Stress, Reward, and the Utility of the Activity-Based Anorexia Model of Anorexia Nervosa.

Authors:  Rachel A Ross; Yael Mandelblat-Cerf; Anne M J Verstegen
Journal:  Harv Rev Psychiatry       Date:  2016 Nov/Dec       Impact factor: 3.732

Review 5.  Pharmacological manipulations in animal models of anorexia and binge eating in relation to humans.

Authors:  M A van Gestel; E Kostrzewa; R A H Adan; S K Janhunen
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 6.  Role of central neurotensin in regulating feeding: Implications for the development and treatment of body weight disorders.

Authors:  Laura E Schroeder; Gina M Leinninger
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-12-27       Impact factor: 5.187

7.  Olanzapine, but not fluoxetine, treatment increases survival in activity-based anorexia in mice.

Authors:  Stephanie J Klenotich; Mariel P Seiglie; Matthew S McMurray; Jamie D Roitman; Daniel Le Grange; Priya Dugad; Stephanie C Dulawa
Journal:  Neuropsychopharmacology       Date:  2012-03-07       Impact factor: 7.853

Review 8.  Dysregulation of brain reward systems in eating disorders: neurochemical information from animal models of binge eating, bulimia nervosa, and anorexia nervosa.

Authors:  Nicole M Avena; Miriam E Bocarsly
Journal:  Neuropharmacology       Date:  2011-11-27       Impact factor: 5.250

9.  The cannabinoid receptor agonist THC attenuates weight loss in a rodent model of activity-based anorexia.

Authors:  Aaron N A Verty; Megan J Evetts; Geraldine J Crouch; Iain S McGregor; Aneta Stefanidis; Brian J Oldfield
Journal:  Neuropsychopharmacology       Date:  2011-03-16       Impact factor: 7.853

10.  α4-GABAA receptors of hippocampal pyramidal neurons are associated with resilience against activity-based anorexia for adolescent female mice but not for males.

Authors:  Yi-Wen Chen; Hannah Actor-Engel; Chiye Aoki
Journal:  Mol Cell Neurosci       Date:  2018-04-22       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.